ZLAB
Price
$38.11
Change
+$1.57 (+4.30%)
Updated
Jun 6 closing price
Capitalization
3.99B
63 days until earnings call
ZYME
Price
$12.60
Change
+$0.47 (+3.87%)
Updated
Jun 6 closing price
Capitalization
845.26M
Interact to see
Advertisement

ZLAB vs ZYME

Header iconZLAB vs ZYME Comparison
Open Charts ZLAB vs ZYMEBanner chart's image
Zai Lab
Price$38.11
Change+$1.57 (+4.30%)
Volume$1.06M
Capitalization3.99B
Zymeworks
Price$12.60
Change+$0.47 (+3.87%)
Volume$362.35K
Capitalization845.26M
ZLAB vs ZYME Comparison Chart
Loading...
ZLAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ZLAB vs. ZYME commentary
Jun 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ZLAB is a StrongBuy and ZYME is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2025
Stock price -- (ZLAB: $30.28 vs. ZYME: $11.23)
Brand notoriety: ZLAB and ZYME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ZLAB: 34% vs. ZYME: 109%
Market capitalization -- ZLAB: $3.99B vs. ZYME: $845.26M
ZLAB [@Biotechnology] is valued at $3.99B. ZYME’s [@Biotechnology] market capitalization is $845.26M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ZLAB’s FA Score shows that 0 FA rating(s) are green whileZYME’s FA Score has 0 green FA rating(s).

  • ZLAB’s FA Score: 0 green, 5 red.
  • ZYME’s FA Score: 0 green, 5 red.
According to our system of comparison, ZLAB is a better buy in the long-term than ZYME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ZLAB’s TA Score shows that 3 TA indicator(s) are bullish while ZYME’s TA Score has 3 bullish TA indicator(s).

  • ZLAB’s TA Score: 3 bullish, 4 bearish.
  • ZYME’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ZLAB is a better buy in the short-term than ZYME.

Price Growth

ZLAB (@Biotechnology) experienced а -7.09% price change this week, while ZYME (@Biotechnology) price change was -5.95% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

ZLAB is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ZLAB($3.99B) has a higher market cap than ZYME($845M). ZLAB YTD gains are higher at: 15.617 vs. ZYME (-23.292). ZYME has higher annual earnings (EBITDA): -108.62M vs. ZLAB (-242.99M). ZLAB has more cash in the bank: 780M vs. ZYME (226M). ZYME has less debt than ZLAB: ZYME (18.5M) vs ZLAB (153M). ZLAB has higher revenues than ZYME: ZLAB (399M) vs ZYME (76.3M).
ZLABZYMEZLAB / ZYME
Capitalization3.99B845M472%
EBITDA-242.99M-108.62M224%
Gain YTD15.617-23.292-67%
P/E RatioN/AN/A-
Revenue399M76.3M523%
Total Cash780M226M345%
Total Debt153M18.5M827%
FUNDAMENTALS RATINGS
ZLAB vs ZYME: Fundamental Ratings
ZLAB
ZYME
OUTLOOK RATING
1..100
538
VALUATION
overvalued / fair valued / undervalued
1..100
47
Fair valued
44
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
4863
P/E GROWTH RATING
1..100
10065
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZYME's Valuation (44) in the Pharmaceuticals Major industry is in the same range as ZLAB (47) in the Biotechnology industry. This means that ZYME’s stock grew similarly to ZLAB’s over the last 12 months.

ZYME's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ZLAB (100) in the Biotechnology industry. This means that ZYME’s stock grew similarly to ZLAB’s over the last 12 months.

ZYME's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as ZLAB (96) in the Biotechnology industry. This means that ZYME’s stock grew similarly to ZLAB’s over the last 12 months.

ZLAB's Price Growth Rating (48) in the Biotechnology industry is in the same range as ZYME (63) in the Pharmaceuticals Major industry. This means that ZLAB’s stock grew similarly to ZYME’s over the last 12 months.

ZYME's P/E Growth Rating (65) in the Pharmaceuticals Major industry is somewhat better than the same rating for ZLAB (100) in the Biotechnology industry. This means that ZYME’s stock grew somewhat faster than ZLAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ZLABZYME
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 12 days ago
79%
Bullish Trend 12 days ago
76%
Momentum
ODDS (%)
Bullish Trend 12 days ago
78%
Bearish Trend 12 days ago
72%
MACD
ODDS (%)
Bullish Trend 12 days ago
82%
Bearish Trend 12 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 12 days ago
85%
Bearish Trend 12 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 12 days ago
82%
Bearish Trend 12 days ago
85%
Advances
ODDS (%)
Bullish Trend 21 days ago
78%
Bullish Trend 20 days ago
81%
Declines
ODDS (%)
Bearish Trend 12 days ago
85%
Bearish Trend 18 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 12 days ago
86%
N/A
Aroon
ODDS (%)
N/A
Bullish Trend 12 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
ZLAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZYME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

ZLAB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZLAB has been loosely correlated with ONC. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLAB jumps, then ONC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZLAB
1D Price
Change %
ZLAB100%
-2.39%
ONC - ZLAB
52%
Loosely correlated
+0.88%
MGTX - ZLAB
36%
Loosely correlated
+0.20%
PRME - ZLAB
35%
Loosely correlated
N/A
VERV - ZLAB
35%
Loosely correlated
-1.17%
ZYME - ZLAB
35%
Loosely correlated
+0.09%
More

ZYME and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZYME has been loosely correlated with KYMR. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ZYME jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZYME
1D Price
Change %
ZYME100%
+0.09%
KYMR - ZYME
50%
Loosely correlated
+2.35%
LENZ - ZYME
47%
Loosely correlated
-2.35%
ABCL - ZYME
46%
Loosely correlated
+3.03%
NRIX - ZYME
46%
Loosely correlated
+2.76%
ABEO - ZYME
45%
Loosely correlated
-2.12%
More